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Abstract.  The objective of the current study was to investigate the mechanism by which the
corpus luteum (CL) of the monkey undergoes desensitization to luteinizing hormone following 
exposure to increasing concentration of human chorionic gonadotrophin (hCG) as it occurs in 
pregnancy. Female bonnet monkeys were injected (im) increasing doses of hCG or dghCG 
beginning from day 6 or 12 of the luteal phase for either 10 or 4 or 2 days. The day of oestrogen 
surge was considered as day '0' of luteal phase. Luteal cells obtained from CL of these animals 
were incubated with hCG (2 and 200 pg/ml) or dbcAMP (2.5, 25 and 100 µM) for 3h at 37°C and 
progesterone secreted was estimated. Corpora lutea of normal cycling monkeys on day 10/16/22 
of the luteal phase were used as controls. In addition the in vivo response to CG and 
deglycosylated hCG (dghCG) was assessed by determining serum steroid profiles following their 
administration. hCG (from 15-90 IU) but not dghCG (15-90 IU) treatment in vivo significantly 
(P < 0·05) elevated serum progesterone and oestradiol levels. Serum progesterone, however, 
could not be maintained at a elevated level by continuous treatment with hCG (from day 6-15), 
the progesterone level declining beyond day 13 of luteal phase. Administering low doses of hCG 
(15-90 IU/day) from day 6-9 or high doses (600 IU/day) on days 8 and 9 of the luteal phase 
resulted in significant increase (about 10-fold over corresponding control P < 0·005) in the ability 
of luteal cells to synthesize progesterone (incubated controls) in vitro. The luteal cells of the 
treated animals responded to dbcAMP (P < 0·05) but not to hCC added in vitro. The in vitro 
response of luteal cells to added hCG was inhibited by 0, 50 and 100% if the animals were injected 
with low (15-90 IU) or medium (100 IU) between day 6-9 of luteal phase and high (600 IU on 
day 8 and 9 of luteal phase) doses of dghCG respectively; such treatment had no effect on 
responsivity of the cells to dbcAMP. The luteal cell responsiveness to dbcAMP in vitro was also 
blocked if hCG was administered for 10 days beginning day 6 of the luteal phase. Though short 
term hCG treatment during late luteal phase (from days 12-15) had no effect on luteal function, 
10 day treatment beginning day 12 of luteal phase resulted in regain of in vitro responsiveness to 
both hCG (P < 0·05) and dbcAMP (P < 0·05) suggesting that luteal rescue can occur even at this 
late stage. In conclusion, desensitization of the CL to hCG appears to be governed by the 
dose/period for which it is exposed to hCG/dghCG. That desensitization is due to receptor 
occupancy is brought out by the fact that (i) this can be achieved by giving a larger dose of hCG 
over a 2 day period instead of a lower dose of the hormone for a longer (4 to 10 days) period and 
(ii) the effect can largely be reproduced by using dghCG instead of hCG to block the receptor 
sites. It appears that to achieve desensitization to dbcAMP also it is necessary to expose the luteal 
cell to relatively high dose of hCG for more than 4 days. 
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1. Introduction 
 
The luteal phase of non-human primates reckoned from the day of oestrogen/LH surge 
extends from 12 to 16 days depending upon the species (Moudgal 1984). The corpus 
luteum (CL) besides producing progesterone (P), synthesizes substantial quantities of 
oestrogen (Stouffer 1988), relaxin (Weiss et al 1976) and inhibin (McLachlan et al 1987). 
Although the CL in the primate is functional for only two weeks in the non-fertile cycle, 
its life span is extended on pregnancy establishment. It is widely accepted that chorionic 
gonadotrophin (CG) initially secreted by the pre-attachment blastocyst (Fishel et al 
1984; Hearn et al 1988) and later on implantation of the embryo, by the syncitiot-
rophoblast (Tullner 1977) is responsible for rescuing the CL from its cyclical imminent 
death (Knobil 1973). 
In a fertile cycle despite a progressive rise in circulating CG, the increment in 
P production by the CL appears to be only short lived, P levels declining at time points 
when CG concentration has reached a maximum. Wilks and Noble (1983) and Ottobre 
and Stouffer (1984) were able to mimic the steroid profile of the fertile cycle in 
non-mated cycling macaques by administering increasing doses of hCG during the 
luteal phase. The luteal cells isolated from the pregnancy simulated animals showed 
desensitization of the adenylate cyclase system to hCG but not to heterologous ligands 
like prostaglandins, PGE2 and PG12 (Vande Voort et al 1988). All the same Ottobre 
et al (1989) observe that desensitization to gonadotrophin in terms of P production 
could also involve an event subsequent to stimulation of adenylate cyclase. In the 
pregnancy simulation model used by earlier workers though hCG was administered for 
10 days the responsiveness of the luteal cells isolated from these animals at the 
termination of the experiment were compared only to cells from day 0 of treatment but 
not to that of cells taken from age matched controls (Vande Voort et al 1988; Ottobre 
et al 1989). Such type of comparison does not appear to be correct as it has been clearly 
demonstrated that the gonadotrophin induced P production by the luteal cell is 
a function of the age of the CL (Stouffer et al 1977; Mukku and Moudgal 1979). Hence, 
in the present study bonnet monkeys were administered hCG for a 10, 4 or 2 day period 
(the treatment being initiated either during early or late luteal phase) and the respon-
siveness of the luteal cells isolated from these animals were compared with that of luteal 
cells isolated from proper age/day match controls. In addition the ability of dghCG, 
a well characterized antagonist of hCG, when administered in vitro to bring about 
luteal cell desensitization in vitro has also been investigated. 
 
2. Materials and methods 
 
2.1 Materials 
 
hCG (CR127 14, 900 units/mg) used for in vitro incubations of the luteal cells was 
provided by Dr G Bialy, NICHD, Bethesda, USA. The deglycosylated hCG (S 2112) 
was a product of Dr Sairam's laboratory in Montreal. In the LH/CG receptor assay 
(Selvaraj and Moudgal 1993) it had an activity equivalent to 12,000 units of hCG/mg. 
In the in vitro monkey luteal cell assay, however, dghCG even at a maximal concentra- 
tion of 100 ng/tube did not evoke a significant steroidogenic response (Selvaraj 1993). 
Tritiated progesterone (88 Ci/mmol) and oestradiol (OE2; 90 Ci/mmol) were purchased 
from Amersham, UK. DMEM was procured from GIBCO, USA. Collagenase, Hepes, 
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BSA, dbcAMP etc., were from Sigma Chemical Co., St. Louis, USA. All other chemicals
used were of analytical grade and procured locally. 
 
2.2 Animals 
 
Healthy adult regularly cycling female bonnet monkeys (Macaca radiata) of 8-12 years 
of age were used. The details of animal husbandry, monitoring of cycle, collection of 
blood samples etc., were as previously described (Ravindranath et al 1989). All the 
animal experiments were cleared by the institutional ethical committee for use of 
laboratory animals for biomedical research. The day of onset of menstrual bleeding was 
considered as the day 1 of the cycle. 
 
2.3 Experimental protocol 
 
Regularly cycling non-mated monkeys were administered increasing doses of hCG 
(Profasi, Serono Laboratories, Randolph, USA) once daily for either 4 or 10 days 
starting from day 6 or 12 of the luteal phase. For the purpose of this study, the day of 
oestrogen surge (day 8-10 of cycle) was considered as day 0 of the luteal phase. It should 
be noted that in these monkeys LH surge occurs within 24 h of 0E2 surge (Selvaraj and 
Moudgal 1993). Monkeys received an increasing dose of hCG-15; 30; 45; 90; 180; 360; 
720; 1,440; 2,880 and 5,760 IU/day—over a 10 day treatment period; when the short 
treatment schedule was used only the first four doses were injected. Deglycosylated 
hCG was administered from day 6 to 9 of luteal phase either at the same dose as hCG 
(15, 30, 45, 90 IU/day) or at 100 IU hCG equivalent/day. The results of such a treatment 
were also compared with that obtained following administration of a high dose (600 
IU/day) of hCG or dghCG on days 8 and 9 only of luteal phase. Mid ventral 
laparotomy was performed under ketamine anaesthesia 24 h after the last injection to 
remove the CL. Corpus luteum of control animals which were administered saline 
instead of hCG was removed on either day 10 or 16 or 22 of the luteal phase. The CL of 
the control animals of day 22 were obtained after the break of the cycle signified by 
menstruation. Blood was collected at 0930h of the day using Vacutainer tubes 
(Becton-Dickinson, USA), serum separated and stored at — 20°C until used for steroid 
estimation. 
 
2.4 Luteal cell digestion and short term incubation 
 
The CL was excised from the ovary by blunt dissection and placed in DMEM 
containing 25 mM Hepes, 0·37% NaHCO3 and 0·1 % BSA (pH 7·4). The luteal tissue 
was washed and subjected to collagenase digestion essentially according to the method 
standardized earlier in the laboratory for monkey thecal tissue (Selvaraj and Moudgal 
1994). In brief the CL was cut into small pieces and digested thrice with collagenase to 
obtain cell suspension which was washed extensively with the medium to remove 
collagenase (Stouffer et al 1976). The luteal cells in the DMEM medium were pre- 
incubated at 37°C for 30 min in a shaker water-bath followed by washing and the cells 
were  suspended in  a  known volume of  medium. Cel ls  were counted in  
a haemocytometer and 5 × 104 viable cells per tube (65-80% viable cells were obtained 
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as determined by trypan blue exclusion test) were incubated in the presence or absence 
of hCG (2 and 200 pg/ml) or dibutryl cAMP (2·5, 25 and 100 µM) in a total volume of 
0·5 ml in 22 × 75 mm ether washed glass tubes for 3 h at 37°C in a shaker water-bath (60 
oscillations per min). A hCG concentration of 200 pg/ml was chosen as it provided 
maximal response in a pilot study with monkey luteal cells. At the end of incubation, 
tubes were transfered to a 20°C freezer until assayed for steroids. 
 
2.5 Hormone assays 
 
Oestradiol (OE2) and P assays were carried out as described elsewhere (Ravindranath 
et al 1989). The serum samples were ether extracted twice and following evaporation of 
the ether the solids were dissolved in gelatin phosphate buffered saline (GPBS). The in 
vitro incubates were assayed for P without any processing. Progesterone antisera used 
was a kind gift of Dr Chandana Das, All India Institute of Medical Sciences, New Delhi 
and the OE2, antibody was a laboratory preparation. Characteristics of the P and OE2
antisera used have been provided earlier by Selvaraj and Moudgal (1994). 
 
2.6 Statistics 
 
Individual experiments were carried out using 3 monkeys per group and the data 
presented are mean ± SEM of replicate experiments. In the in vivo studies to determine 
the steroid output over a specified period of time, the area under the curve (summation 
of steroid concentration) of individual monkeys was computed and analysed using 
a GP2 software. Differences between the serum oestradiol and progesterone profile of 
control and experimental animals was statistically evaluated by ANOVA followed by 
Schefee F test using Macintosh based State view 512 + software developed by Brain 
Power Inc., Ca, USA. In the in vitro incubation study the response to each level of 
hormone addition was determined in triplicate and as the cells from each of the 
monkeys were analysed separately at each level of hormone the data represents mean of 
9 determinations. Treatment differences were analysed by Student's t-test. 
 
3. Results 
 
3.1 Effect of hCG/dghCG administration during luteal phase on serum steroid levels 
 
Administration of hCG to the cycling monkey for four days during the early luteal 
phase (day 6-9) resulted in an increase in both serum P (by 78%, P < 0·05) and OE2 (by 
20%) over the control (figure 1, b vs a and table 1). However, when dghCG was injected 
at a dose level equal to that of hCG (viz., at 15, 30, 45 and 90 IU hCG equiv/day) from 
days 6 to 9 of the luteal phase there was no significant change in either P or OE2 
(figure 1, c vs a and table 1). Administration of 100 IU/day dghCG over the same 4 day 
period (days 6-9 of luteal phase) resulted in reduction in serum P (by 55%, P < 0·05)
levels over the controls (figure 1, d vs a and table 1). Injection of 600 IU hCG on days 
8 and 9 of luteal phase brought about a 46% (P < 0·05) increase in serum P level over 
the control. The same dose of dghCG did not bring about a change in total P produc- 
tion over the control (figure 1, e and f and table 1). Though the first injection of dghCG 
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Figure 1. Effect of administration of hCG/dghCG for 4 days (from day 6-9) or for 2 days (on 
days 8 and 9) of the luteal phase on serum steroid level in female bonnet monkeys. (a) Control; 
(b) hCG administered on days 6-9 of luteal phase (15, 30, 45 and 90 IU/day); (c) dghCG 
administration as in b; (d) dghCG on days 6-9 luteal phase (100 IU/day); (e) hCG on days 8 and 
9 of luteal phae (600 IU/day) and (f) dghCG on days 8 and 9 (600 IU/day). Arrows indicate the 
days of hormone treatment. 
*P < 0·05 compared to control, (a) P < 0·05 compared to day 5, (b) P < 0·05 compared to day 8, 
(c) P < 0·05 compared to day 8 and 9 (Scheffe F test after ANOVA). 
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Table 1. Effect of hCG/dghCG injections during the early luteal phase on steroid 
production. 
Serum steroid concentrations between days 6-10 or 8-10 of the luteal phase (depend- 
ing on the day of initiation of treatment) was used to calculate the area under the curve 
using GP2 software. 
*P < 0·05, compared to the control, Student's ‘t’ test. 
n = 3/ group. Data is mean ± SEM. 
 
 
given on day 8 of luteal phase did not result in an increase in serum P over the basal 
level the second dghCG injection given on day 9 of luteal phase significantly elevated 
P levels over the basal (P < 0·05). The response to second dose is perhaps attributable 
to the presence of low level of hCG ( < 5%) contamination in the dghCG preparation. 
Continuing hCG treatment for a 10 day period as per schedule starting from day 6 of 
luteal phase, resulted in daily increment in P levels. Between days 8-13 there was no 
significant change in the elevated P levels but beyond this the P level declined despite 
the animals receiving on the last three days of treatment high doses of hCG (1440, 2880 
and 5760 IU). The serum E level in contrast continued to be maintained at an elevated 
level (P < 0.05) (figure 2, a and b and table 2) throughout the experimental period. The 
fold increment in progesterone produced by hCG treatment ranged between 1·3 to 
2·0-fold irrespective of the time of initiation (day 6 vs day 12 of luteal phase) or duration 
of hCG treatment (for 4 or 10 days) (figure 2b vs c and figure 3b, tables 1 and 2). The net 
amount of progesterone produced following hCG treatment, however, was higher if the 
treatment was scheduled between days 6-9 instead of days 12-15 of luteal phase 
(table 2). 
Substantial increase in oestrogen secretion occurred only following hCG treatment 
for a 10 day period (compare figures 2b and 3b with lb and 2c) and this reached 
significant proportion (2·6 vs 1·5-fold) when the 10 day treatment was initiated starting 
from day 12 instead of day 6 of luteal phase (table 2). 
 
 
3.2 Effect of hCG/dghCG administration on the weight of the corpus luteum 
 
The weight of the corpus luteum increased (P < 0·025) in response to hCG but not 
dghCG treatment. This was particularly evident when hCG treatment was restricted to 
a 2 or 4 day period in the early luteal phase (table 3). In a normal cycle the luteal weight 
declines significantly with age [compare CL wt of day 10 with that of day 22 (table 3)]. 
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Figure 2. Serum steriod profile of female bonnet monkeys which received different doses of 
hCG during early (for 10 days) and late (for 4 or 10 days) luteal phase. (a) control; (b) hCG 
administered on days 6-15 of luteal phase (15, 30, 45, 90, 180, 360, 720, 1440, 2880 and 
5760 IU/day) and (c) hCG administered on days 12-15 of the luteal phase with the first four
doses of hCG as of b. *P < 0·05 compared to control (ANOVA followed by Scheffe F test).
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Table 2.  Effect of increasing dose of hCG administration for a 10 day period during
early (days 6-16) and late (days 12-22) luteal phase on serum steroid production.
Total oestrogen and progesterone produced during the period of treatment was 
determined by calculating the area under the curve using GP2 software. The data 
presented is mean ± SEM of 3 animals per group. 
*P <0·05; **P <0·025 compared to the control, Student's 't' test. 
†For the control animals the area under the curve was calculated till day 20 of the cycle. 
 
 
 
This decline in CL weight was prevented following hCG treatment for a 10 day period 
starting from day 12 of luteal phase, a typical result perhaps of luteal rescue.
 
 
3.3 Short term incubation studies with the isolated luteal cells 
 
Though maximal basal P production (incubated control) by luteal cells from control 
animals was observed for cells isolated from day 16 of the luteal phase (ng progesterone 
produced by 5 × 104 cells/3h—day 10: 1·88 ± 0·28 vs day 16: 3·52 ± 0·28 and day 22:
1·42 ± 0·12), the responsiveness to added hCG/dbcAMP in vitro was maximal for luteal 
cells isolated from day 10(3-4-fold), whereas those from day 16 and 22 showed no 
increment in P production (tables 4 and 5). The basal secretion of progesterone by the 
luteal cells isolated from animals treated with hCG in vivo during the early luteal phase 
(from days 6-9 or on days 8 and 9) was significantly increased (10-fold, P <0·005) 
compared to cells from animals which received saline alone (table 4). The luteal 
cells of animals treated with high doses of dghCG (600 IU/day) on day 8 and 9 also 
exhibited elevated basal secretion of progesterone (table 4). The luteal cell preparations 
which showed high basal secretion of progesterone failed to respond to hCG added in 
vitro (table4). Their ability to respond to dbcAMP, however, appeared not altered 
(table 4). 
Compared to the good response (3·5-fold) the luteal cells (isolated on day 10 of luteal 
phase) from control animals showed to added hCG (200 pg) the cells from animals 
treated with low and medium doses of dghCG in vivo showed only a 2·0 and 1·7-fold 
increment in P production respectively (table 4). Relatively the luteal cells from animals 
treated with high dose of dghCG (600 IU/day × 2) in vivo, did not respond to added 
hCG in vitro. In the dghCG treated groups the responsiveness to dbcAMP, however, 
remained unaltered from the control (table 4). The desensitization obtained with low 
and medium doses of in vivo dghCG treatment becomes significant as at these doses 
there was no significant increase in in vitro basal progesterone production. 
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Figure 3. Serum steroid profile of female bonnet monkeys administered hCG from the late 
luteal phase. (a) control (refers to day of menses) and (b) KG administered from days 12-21 of
the luteal phase (15, 30, 45, 90, 180, 360, 720, 1440, 2880 and 5760 I U/day). *P < 0·05 (Scheffe 
F lest after ANOVA). 
 
 
Treatment with hCG for a 10 day period starting from day 6 of luteal phase resulted in 
total desensitization of the day 16 CL as the cells isolated from such corpora lutea failed to 
respond to both added hCG and dbcAMP. Though the day 16 luteal cells of control 
monkeys did not show a dose dependent increase in P production to added hCG and 
dbcAMP (table 5), the cells of hCG treated monkeys in comparison showed a uniform 
30% reduction in basal P output in vitro (table 5). Compared to the non-responsive state of 
the day 22 CL of control monkeys, the cells from the in vivo hCG treated group (day 12-21) 
did respond to the in vitro addition of 200 pg/ml hCG (P < 0·05) and 100 µM dbcAMP 
(P < 0·05) thus providing another proof of luteal rescue (table 5). 
 
4. Discussion 
 
The objective of the current study is primarily to understand why luteal rescue initiated 
during a fertile cycle is not sustained despite continuing increase in CG level. The ability 
of exogenous hCG to rescue CL from an iminent cyclical death has been shown in the 
current study by demonstrating that hCG injection during the luteal phase of the 
non-fertile cycle of the monkey results not only in maintenance of serum P at 
a heightened level for a longer duration but also in an increase in luteal cell P output in 
vitro (incubated controls) and an increase in overall luteal weight. The overall trophic 
effect, however, appeared dependent on the time hCG treatment is initiated as well as the 
dose and duration of the treatment. We have also observed that progesterone 
production is maintained at a higher level for a longer period (≈ 8 days) if hCG 
treatment is initiated in the early luteal phase and this essentially confirms the earlier 
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Table 3.  Effect of hCG/dghCG administration during the luteal phase on the weight
of the corpus luteum.
Note that day 10, 16 and 22 of lutel phase represent days 20, 26 and 32 of cycle. 
n = 3 in each group. 
*P < 0·025; **P< 0·001 compared to the day matched control. 
 
 
observation of Ottobre and Stouffer (1984) in the rhesus monkey and that of Ravin- 
dranath (1988) in the bonnet monkey. 
In the current study we have employed dghCG, a well characterized hCG antagonist 
to better understand how luteal desensitization to continuous hCG stimulus is affected. 
While administration of low doses (15-90 IU) of dghCG between days 6-9 of luteal 
phase did not result in any change in total progesterone produced, injection of 100 IU of 
dghCG over the same period did bring about a marked reduction (by 54%, P < 0·05) 
in progesterone production compared to the untreated controls (table 1). Though 
the circulating half-life of dghCG is known to be low it is reported to stay bound to 
the receptor for a much longer time compared to hCG (Sairam et al 1985). It is possible 
such prolonged occupancy of the receptor by dghCG is responsible for block in response 
not only to endogenous LH but also to hCG addition during in vitro incubation. Unlike 
hCG which showed a consistent ability to increase luteal weight over age matched controls 
(an expression of trophic effect), dghCG interestingly, at all three doses tried did not bring 
about an increase in luteal weight (table 2). The increment in luteal weight, it is felt, should 
be viewed as a true expression of luteotropic activity. The significance of this is brought out 
better when one considers that ten day hCG injection regimen starting from the late luteal 
phase prevented the normal decline in the luteal weight seen towards the end of cycle in the 
control group (table 3). 
Earlier workers have demonstrated that responsiveness of the CL to added hCG in vitro 
varies with the age of the CL (Stouffer et al 1977; Mukku and Moudgal 1979; Wilks and 
Noble 1983). The current study has clearly shown that the ability of luteal cell to synthesize 
progesterone in vitro in the absence of added gonadotrophin is maximal for luteal cells of 
day 16 of luteal phase whereas with added hCG or dbcAMP, the maximal response is 
exhibited by the young day 10 luteal cells. This suggests the presence of an inverse 
relationship between in vitro basal progesterone production rate and responsiveness to 
added LH/hCG. As the total receptor concentration of the luteal cell has been observed to 
remain unchanged during the luteal phase (Ottobre and Stouffer 1986), response to 
exogenous gonadotropin appears to be determined by the availability of 'free receptors' at 
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Table 5.  In vitro responsiveness of luteal cells isolated on day 16/22 of the luteal phase.
hCG was administered increasing doses-15, 30, 45, 90, 180, 360, 720, 1440, 2880 and 5760 IU/day either 
from day 6/12 of luteal phase for 4/10 days and the luteal cells obtained from the corpus luteum of these 
animals on either day 16 (group I-III) or 22 (groups IV and V) of the luteal phase were checked for their 
responsiveness as described in the text. 
*P < 0·05 compared to the respective incubated control. 
Mean ± SEM (n = 3 in each group). 
 
 
any given time and this seems to be a function of the period and/or the dose of LH/CG the 
luteal cell is pre-exposed to. It is to be presumed that the luteal cells of day 16 CL relative to 
that of day 10 CL exhibit a greater degree of LH receptor occupancy by endogenous LH 
and consequently are less responsive to added CG in vitro. Cameron and Stouffer (1982) 
have shown that the binding affinity of LH or hCG to the luteal cell receptor is essentially 
similar and Ottobre and Stouffer (1986) have reported that receptor occupancy increase 
with exogenous hCG treatment. 
The observation that luteal cells of monkeys treated with increasing doses of hCG in tiro 
respond to addition of dbcAMP but not hCG in vitro clearly indicates that desensitization 
is affected by interfering with adenylate cyclase activation leading to cAMP production. 
The use of dghCG, an antagonist capable of binding hCG receptor but not eliciting 
a response, in the current study permits us to infer that desensitization is primarily achieved 
due to greater than normal occupancy of the receptor by the hCG/dghCG injected. It is 
possible that the endogenous LH load on the receptor also increases with the age of 
the CL. The fact that the luteal cells taken on day 16 of luteal phase produce greater 
amounts of basal progesterone compared to that of day 10 of luteal phase (day 16: 
3·52 ± 0·28 vs day 10:1·88 ± 0·28 ng progesterone) perhaps is a reflection of this phenom-
enon and appears to be inversely related to the response to LH added in vitro, increment in 
P secretion effected by addition of 200 pg hCG being 3·5-fold for day 10 compared to 
1·2-fold for day 16 CL. By giving exogenous hCG or dghCG in vitro we could be 
precipitating the loss of responsivity to added hCG in vivo (desensitization) and this could 
be consequence of increase in the rate/extent of receptor occupancy by the in vivo CG 
treatment. This becomes particularly evident when one examines the in vitro responsive-
ness of luteal cells of animals treated with dghCG (100 IU) in vivo to addition of hCG 
(200 pg/ml). The fold increment in P secretion was reduced by 50% (fold increment control 
3·5 vs dghCG 1·7, P < 0·05). 
It is evident from the current study that while the luteal cell of normal day 16 luteal phase 
had lost its responsiveness to dbcAMP, the day 10 luteal cell pre-exposed to hCG for only 
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2 or 4 days still retained its ability to respond to dbcAMP. However, desensitization to 
dbcAMP could be achieved by prolonging (by 10 days) the exposure of the luteal tissue to 
hCG action in vivo suggesting thereby that desensitization at the post cAMP stage is 
a secondary effect. 
The reason why continuous hCG administration results in decline in P but not OE2 
production from the luteal tissue has been puzzling investigators. A recent study of Benyo 
et al (1993) has shown that there was a dramatic increase in mRNA levels for the aromatase 
enzyme and low density lipoprotein receptor in luteal tissue of animals given hCG both in 
early and late luteal phase. The difference we observe in P and E secretory pattern following 
hCG stimulus in vivo could be explained if we assume that the granulosa lutein and thecal 
lutein cells of the CL have differential sensitivity to hCG desensitization. Our recent studies 
have shown that while the in vitro responsiveness of granulosa cells aspirated from follicles 
of monkeys specifically deprived of LH support for 48 h (by LH antibody treatment), to 
added hCG was significantly inhibited, the thecal cell responsivity to added hCG in vitro 
remained unaltered (Selvaraj and Moudgal 1994). These results suggested that there are 
differences in the sensitivity of the follicular thecal and granulosa cell LH receptor 
mechanism to up regulation and we now postulate that this could be true for down 
regulation of lutenized thecal and granulosa cells also. Since the thecal cells are known to 
produce oestrogen (Channing 1980) it is probable that the lack of reduction in E output 
following continuous hCG treatment is due to these cells not being desen-sitized by hCG 
treatment. This can only be verified if the luteal cell derived from the two cell types are 
examined separately for susceptibility to desensitization. In support of this is the observa- 
tion of Marut et al (1983) that following aspiration of granulosa cells from the preovulatory 
follicle, progesterone, but not oestrogen secretion declines. 
It appears from the current study that desensitization obtained by exposing luteal cells to 
hCG for short periods is perhaps restricted to the first event in hormone action viz. 
adenylate cyclase activation and cAMP production. These desensitized cells unlike those 
exposed to hCG action for long durations (for 10 days or normal day 16 of luteal phase) 
continue to be responsive to cAMP. The current study shows that desensitization can be 
achieved by exposing the luteal tissue in vivo not necessarily to a long duration of hCG 
treatment but to a relatively higher concentration of hCG for shorter durations. Secondly, 
by using dghCG as the ligand it has been possible to demonstrate without bringing about 
any increment in in vivo P production that there is a correlation between threshold of 
receptor occupancy and desensitization. 
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